This inventor holds 327 USPTO granted patents and 128 published patent applications, plus 41 CIPO patents and 62 EPO patents, primarily in RNA Therapeutics (CPC class C12N2310-14). Top assignees: Alnylam Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Arbutus Biopharma Corporation. Active years: 1995-2026.
Inventors with similar research interests:
Location History:
- La Costa, CA (US) (2004)
- Carlsbad, CA (US) (1995 - 2013)
- Weston, MA (US) (2005 - 2024)
- Cambridge, MA (US) (2011 - 2024)
Company Filing History:
169 out of 465 
125 out of 1,035 
18 out of 57 
Years Active: 1995-2026
Areas of Expertise:
Title: Muthiah Manoharan: Innovator Extraordinaire in RNAi and Drug Delivery Technologies
Introduction:
Muthiah Manoharan is a highly accomplished inventor and researcher based in Cambridge, MA, where he has made significant contributions to the fields of RNA interference (RNAi) and drug delivery technologies. With an impressive portfolio of 296 patents and an extensive career with leading pharmaceutical companies, Manoharan has cemented his position as a pioneering figure in the realm of biotechnology.
Latest Patents:
Two notable patents among Manoharan's recent innovations are "Serpina1 iRNA compositions and methods of use thereof" and "Biodegradable lipids for the delivery of active agents." The former patent focuses on RNA interference agents targeting the Serpina1 gene, providing methods to inhibit its expression and potentially treat individuals with Serpina1 associated diseases, particularly liver disorders. The latter patent emphasizes the usage of cationic lipids with biodegradable groups for the efficient delivery of active agents like nucleic acids within lipid particles.
Career Highlights:
Throughout his illustrious career, Muthiah Manoharan has demonstrated his expertise by working with renowned pharmaceutical companies. He has notably contributed to the success and advancement of Alnylam Pharmaceuticals, Inc., recognized for its groundbreaking RNAi therapeutics research and development. Additionally, Manoharan has made significant contributions at Isis Pharmaceuticals, Inc., a company specializing in RNA-targeted drug discovery and development.
Collaborations:
Manoharan has been fortunate to collaborate with several leading researchers and scientists in the industry. Notably, he has worked alongside distinguished individuals such as Kallanthottathil G Rajeev and Phillip Dan Cook. These collaborations have facilitated knowledge exchange and the development of groundbreaking advancements in the RNAi and drug delivery fields, further enhancing Manoharan's expertise and influence.
Conclusion:
Muthiah Manoharan's exceptional contributions to the fields of RNAi and drug delivery technologies have positioned him as an outstanding innovator. His extensive patent portfolio highlights his cutting-edge research in RNA interference agents, particularly those targeting the Serpina1 gene, as well as his focus on developing innovative lipid-based drug delivery systems. With his noteworthy career trajectory and collaborations with esteemed researchers, Manoharan continues to play a pivotal role in advancing the field of biotechnology.